tailieunhanh - HoSAGE: Sarcopenia in older patient with intermediate / high-risk prostate cancer, prevalence and incidence after androgen deprivation therapy: Study protocol for a cohort trial

Sarcopenia is defined by a loss of muscle strength associated to a decrease in skeletal muscle mass. Ageing greatly contributes to sarcopenia as may many other factors such as cancer or androgen deprivation thera‑ pies (ADT). | Couderc et al. BMC Cancer 2022 22 78 https s12885-021-09105-8 STUDY PROTOCOL Open Access HoSAGE sarcopenia in older patient with intermediate high-risk prostate cancer prevalence and incidence after androgen deprivation therapy study protocol for a cohort trial Anne Laure Couderc1 2 3 Patrick Villani1 2 3 Julie Berbis4 Emilie Nouguerède1 2 Dominique Rey1 2 Dominique Rossi5 7 Éric Lechevallier6 7 Delphine Badinand8 Cyrille Bastide5 7 Gilles Karsenty6 7 Romain Boissier6 7 Kahena Amichi9 and Xavier Muracciole8 Abstract Background Sarcopenia is defined by a loss of muscle strength associated to a decrease in skeletal muscle mass. Ageing greatly contributes to sarcopenia as may many other factors such as cancer or androgen deprivation thera pies ADT . This cohort study aims to evaluate 1 the prevalence of muscle disorders and sarcopenia in older patients before initiation of intermediate to high risk prostate cancer treatment with ADT and radiotherapy and 2 the occur rence and or aggravation of muscle disorders and sarcopenia at the end of cancer treatment. Methods This cohort study is monocentric and prospective. The primary objectives are to determine the risk fac tor of sarcopenia prevalence and to study the relationship between ADT and sarcopenia incidence in patients 70 years and older with histologically proven localized or locally advanced prostate cancer addressed to a geriatrician G8 score 14 for comprehensive geriatric assessment CGA in Marseille University Hospital. Secondary objectives encompass measurement of sarcopenia clinical criteria along prostate oncological treatment evaluation of the quality of life of patients with sarcopenia evaluation of the impact of socio-behavioral and anthropological factors on sarcopenia evolution and incidence finally the evaluation of the impact of ADT exposure on sarcopenia. Sarcopenia prevalence was estimated to be between 20 and 30 therefore the study will enroll 200 patients. Discussion The current .